Investment Analysts’ Recent Ratings Updates for Blueprint Medicines (BPMC)

A number of research firms have changed their ratings and price targets for Blueprint Medicines (NASDAQ: BPMC):

• 2/14/2025 – Blueprint Medicines was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/14/2025 – Blueprint Medicines had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
• 2/14/2025 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
• 2/13/2025 – Blueprint Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $128.00 price target on the stock, up previously from $124.00.
• 2/13/2025 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 2/4/2025 – Blueprint Medicines had its price target raised by analysts at JPMorgan Chase & Co. from $126.00 to $129.00. They now have an “overweight” rating on the stock.
• 1/27/2025 – Blueprint Medicines had its price target raised by analysts at Piper Sandler from $109.00 to $119.00. They now have a “neutral” rating on the stock.
• 1/15/2025 – Blueprint Medicines had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
• 1/13/2025 – Blueprint Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $124.00 price target on the stock, down previously from $135.00.
• 1/13/2025 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
• 1/2/2025 – Blueprint Medicines had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $140.00 price target on the stock.

Blueprint Medicines Stock Down 2.0 %

BPMC traded down $1.92 during mid-day trading on Tuesday, reaching $92.02. 601,775 shares of the stock were exchanged, compared to its average volume of 1,025,215. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The stock has a market capitalization of $5.85 billion, a PE ratio of -43.61 and a beta of 0.62. The company has a 50 day moving average price of $99.60 and a two-hundred day moving average price of $94.43. Blueprint Medicines Co. has a 1 year low of $80.42 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. As a group, research analysts anticipate that Blueprint Medicines Co. will post -3.63 EPS for the current year.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36. Following the sale, the chief operating officer now directly owns 67,109 shares of the company’s stock, valued at $7,391,385.26. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 15,161 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 in the last ninety days. Company insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in shares of Blueprint Medicines in the third quarter worth about $32,000. R Squared Ltd purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth about $51,000. Covestor Ltd lifted its holdings in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after buying an additional 403 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth about $65,000. Finally, Thematics Asset Management purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth about $72,000.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.